PMID- 34560822
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220316
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
VI  - 73
IP  - 4
DP  - 2022 Apr
TI  - Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac 
      Mortality in Heart Failure with Reduced Ejection Fraction.
PG  - 350-356
LID - 10.1177/00033197211047329 [doi]
AB  - The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan and 
      sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin have been shown 
      to reduce rehospitalization and cardiac mortality in patients with heart failure 
      (HF) with reduced ejection fraction (HFrEF). We aimed to compare the long-term 
      cardiac and all-cause mortality of ARNI and dapagliflozin combination therapy 
      against ARNI monotherapy in patients with HFrEF. This retrospective study 
      involved 244 patients with HF with New York Heart Association (NYHA) class II-IV 
      symptoms and ejection fraction </=40%. The patients were divided into 2 groups: 
      ARNI monotherapy and ARNI+dapagliflozin. Median follow-up was 2.5 (.16-3.72) 
      years. One hundred and seventy-five (71.7%) patients were male, and the mean age 
      was 65.9 (SD, 10.2) years. Long-term cardiac mortality rates were significantly 
      lower in the ARNI+dapagliflozin group (7.4%) than in the ARNI monotherapy group 
      (19.5%) (P = .01). Dapagliflozin [Hazard Ratio (HR) [95% Confidence Interval 
      (CI)] = .29 [.10-.77]; P = .014] and left ventricular ejection fraction (LVEF) 
      [HR (95% CI) = .89 (.85-.93); P < .001] were found to be independent predictors 
      of cardiac mortality. Our study showed a significant reduction in cardiac 
      mortality with ARNI and dapagliflozin combination therapy compared with ARNI 
      monotherapy.
FAU - Karabulut, Umut
AU  - Karabulut U
AUID- ORCID: 0000-0002-3947-9173
AD  - Department of Cardiology, 64296Acibadem International Hospital, Istanbul, Turkey.
FAU - Keskin, Kudret
AU  - Keskin K
AD  - Department of Cardiology, 64159Istanbul Sisli Hamidiye Etfal Training and 
      Research Hospital, Istanbul, Turkey.
FAU - Karabulut, Dilay
AU  - Karabulut D
AD  - Department of Cardiology Istanbul, 147005Istanbul Bakirkoy Dr.Sadi Konuk Training 
      and Research Hospital, Istanbul, Turkey.
FAU - Yigit, Ece
AU  - Yigit E
AD  - Department of Internal Medicine, 218502Istanbul Pendik Medipol University 
      Hospital, Istanbul, Turkey.
FAU - Yigit, Zerrin
AU  - Yigit Z
AD  - Department of Cardiology, 532719Istanbul University, Cerrahpasa Cardiology 
      Institute, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210924
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucosides)
RN  - 0 (Tetrazoles)
RN  - 17ERJ0MKGI (sacubitril)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 80M03YXJ7I (Valsartan)
SB  - IM
MH  - Aged
MH  - Aminobutyrates
MH  - Angiotensin Receptor Antagonists
MH  - Benzhydryl Compounds
MH  - Biphenyl Compounds/pharmacology
MH  - Drug Combinations
MH  - Glucosides
MH  - *Heart Failure
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Tetrazoles/adverse effects
MH  - Treatment Outcome
MH  - Valsartan/pharmacology/therapeutic use
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - combination therapy
OT  - dapagliflozin
OT  - heart failure
OT  - mortality
OT  - sacubitril
OT  - valsartan
EDAT- 2021/09/26 06:00
MHDA- 2022/03/17 06:00
CRDT- 2021/09/25 05:20
PHST- 2021/09/26 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2021/09/25 05:20 [entrez]
AID - 10.1177/00033197211047329 [doi]
PST - ppublish
SO  - Angiology. 2022 Apr;73(4):350-356. doi: 10.1177/00033197211047329. Epub 2021 Sep 
      24.